The effects of cholesterol-lowering medication on skeletal muscle functioning

Gepubliceerd: 20-10-2015 Laatst bijgewerkt: 07-12-2022

Primary aim: 1. To investigate whether differences exist in the mitochondrial energy generating capacity of skeletal muscle of statin users with SAMS compared to statin users without SAMS and controls (non-statin users). Secondary aims: 2A. To...

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Observationeel onderzoek, zonder invasieve metingen

Samenvatting

ID

NL-OMON22168

Bron
Nationaal Trial Register

Verkorte titel
STATEX

Aandoening

Statin associated muscle symptoms
muscle functioning (contraction efficiency, muscle relaxation, muscle fatigue)
whole body aerobic fitness
mitochondrial function

Ondersteuning

Primaire sponsor: Radboud University Nijmegen Medical Centre
Overige ondersteuning: ZonMW Veni

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

o Energy generating capacity of muscle mitochondria (in muscle biopsy)
o Muscle function (= muscle force, contractile speed, relaxation and fatigability)
o Cardiorespiratory fitness (incremental cycling test)

Toelichting onderzoek

Achtergrond van het onderzoek

Statins are among the most widely prescribed medications in developed countries. They markedly reduce the incidence of ischemic heart disease and stroke by lowering low-density lipoprotein (LDL) cholesterol. Although statins have demonstrated remarkable clinical safety, muscle toxicity is a frequent limiting factor in the administration of statin therapy. Statin-associated muscle symptoms (SAMS) exist in a spectrum from mild muscle symptoms (e.g. fatigue, myalgia, cramps, weakness, reported in 9-27% of patients) to rare life-threatening rhabdomyolysis. The occurrence of diffuse muscle aches significantly limits quality of life and prompts many patients to quit this life-saving medication. As lipid-lowering treatments are intended for long-term use, statin non-adherence has a marked impact on cardiovascular risk management an increases mortality risk.

The mechanisms underlying statin-induced muscular side effects remain incompletely understood. Both in vivo and ex vivo [8] evidence is present for an impaired mitochondrial oxidative capacity in skeletal muscle of patients on statin therapy. Recently, Prof. Frans Russel from the department of Pharmacology and Toxicology at the Radboudumc examined muscle biopsies of subjects with SAMS and found that statins can in fact accumulate in skeletal muscle and specifically bind to and inhibit the activity of complex III of the mitochondrial respiratory chain (Schirris, Smeitink, Russel, Cell Metabolism accepted). These novel data strongly support an inhibitory role of statins on mitochondrial function. Unfortunately no comparison was made with individuals on statins without complaints nor with subjects that do not use statins. Therefore, the first aim of this study is to investigate whether we can detect differences in the mitochondrial energy generating capacity of skeletal muscle between 1. statin users with SAMS compared to 2. statin users without SAMS and compared to 3. controls (non-statin users). The three groups will be matched for age, sex and physical activity level.

Statin-induced effects on skeletal muscle cause a decrease in aerobic capacity. The fact that aerobic fitness is a strong predictor for all-cause mortality but also diabetes risk - which has

recently been coupled to statin use -, emphasizes the need to clarify the interaction between statins and skeletal muscle function. There are only a limited number of studies that examined the effects of statins on muscle performance, muscle function and on aerobic capacity. Therefore, the secondary aim of this study is (A). to investigate if statin users with SAMS have an altered muscle function and cardiorespiratory fitness compared to statin users without SAMS and controls (non-statin users) and (B). if this relates to the mitochondrial energy generating capacity of the muscle.

Doel van het onderzoek

Primary aim:

1. To investigate whether differences exist in the mitochondrial energy generating capacity of skeletal muscle of statin users with SAMS compared to statin users without SAMS and controls (non-statin users).

Secondary aims:

2A. To investigate if statin users with SAMS have an altered muscle function and cardiorespiratory fitness compared to statin users without SAMS and controls (non-statin users)

2B. To investigate if altered muscle function and cardiorespiratory fitness in statin users relates to the mitochondrial energy generating capacity of the muscle.

Onderzoeksopzet

The participants will visit the lab two times. On measurement day 1, the medical screening will take place. If subjects are found eliglible, the muscle function measurement will be performed, which will be followed by an incremental cycling test. On day 2, a blood sample will be withdrawn in the overnight fasted state, which will be followed by the collection of a muscle biopsy

Onderzoeksproduct en/of interventie

All study participants will undergo a medical screening session of 1 hour to determine whether they comply with the in- and exclusion criteria. The medical screening will contain an elaborate physical examination and participants are asked to fill out two short questionnaires on muscle complaints (Short-form McGill pain questionnaire and Short-form Brief Pain Inventory). If participants are found eligible for inclusion, we will invite participants to the lab to perform an incremental cycling test and a muscle contractile function test. For these tests, participants are instructed to refrain from strenuous exercise 24h prior to the tests. On a seperate day, in the overnight fasted state, a blood withdrawal will take place to check the

lipid profile, liver enzymes and kidney function, creatine kinase, pyruvate, lactate and glucose levels, which will be followed by the collection of a muscle biopsy.

Contactpersonen

Publiek

Radboud University Nijmegen Medical Centre - Department of Physiology

Silvie Timmers
PO BOX 9101

Nijmegen 6500HB
The Netherlands
+31 24 361 42 22

Wetenschappelijk

Radboud University Nijmegen Medical Centre - Department of Physiology

Silvie Timmers
PO BOX 9101

Nijmegen 6500HB
The Netherlands
+31 24 361 42 22

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

o Age: 18-70 years old

o Current statin user (group 1-2) for at least 3 months

o Mentally able/ allowed to give informed consent

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

o Familial hypercholesterolemia

o History of a cardiovascular event within 1 year of study participation

o Impaired liver function (ALAT, ASAT, gamma-GT > 3x ULN)

o Known hereditary muscle defect, creatine kinase >5 x ULN

o known mitochondrial disease

o Medication known to potentially interfere with muscle metabolism (fibrates, Beta blockers, laxatives, diuretics, bronchodilatators)

o Impaired kidney function (creatinine <50 or > 100 µmol/l)

o Diabetes mellitus

o Engagement in exercise for more than two hours per week

Onderzoeksopzet

Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blindering:	Open / niet geblindeerd
Controle:	Actieve controle groep

Deelname

Nederland

Status:	Werving gestart
(Verwachte) startdatum:	01-10-2015
Aantal proefpersonen:	30
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies

Datum:	20-10-2015
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL5248
NTR-old	NTR5505
Ander register	: 2015-1836 // NL52337.091.15

Resultaten